I’ve spent the last week describing what the.lab does. Ten microservices. Millions of whole-genome variants annotated. CRISPR design, off-target analysis, clinical trial matching, factor dosing, bleeding assessment — all running on containerized infrastructure that costs less per month than a single Sanger sequencing run at a university core facility.

Today I want to talk about what the.lab becomes. Because there’s a difference between a platform that impresses people who understand genomics and a platform that pays for itself. We’ve been doing the first thing. It’s time to think about the second.

This is the post where we get serious about money. Ish.

The pipeline

Before anyone draws up a pitch deck, the inventory matters. Not what we could build. What’s running right now, in production, responding to API calls.

A patient genome enters the system. Ten independent, containerized services process it in parallel. Six categories of output emerge — disease risk panels, CRISPR therapeutic designs, pharmacogenomic profiles, clinical trial matches, polygenic risk scores, and immunological typing.

All of this completes in hours. At zero marginal cost. On bare metal. No vendor contracts, no per-seat licenses, no queue.

This is the same computational analysis that a university genomics core delivers in two to six weeks for $500 to $3,000 per genome. We’re not faster because we cut corners. We’re faster because there are no corners to cut.

The service tiers

Not everything is equally ready for market. Some services are production APIs today. Others need wrapping. A few need validation partnerships. Here’s how we think about the layers:

Tier 1 is packaging, not engineering. The CRISPR design suite, the pharmacogenomic reporting engine, and the amplicon quantification service are live APIs right now. They need billing integration and clean documentation. Revenue timeline: weeks.

Tier 2 is REST wrapping. The variant interpretation engine, the HLA typing service, the bleeding disorder screening panel, and the polygenic risk score calculator all exist in the analysis pipeline. They need standalone API packaging, output formatting, and per-service documentation. Revenue timeline: months.

Tier 3 is scaling. Whole-genome-in-a-box, family trio analysis, and rare disease acceleration require clinical validation partnerships and logistics infrastructure. These are the services that change how medicine works. They also need more time and more investment. Revenue timeline: quarters.

The important thing is that Tier 1 doesn’t block Tier 2 or 3. Each tier is independent. We can generate revenue from Tier 1 while building Tier 2, and fund Tier 2 from Tier 1 revenue. This isn’t a sequential roadmap. It’s a portfolio.

The services that already work

Let me give you the specifics, because specifics are what separate a real business from a slide deck.

CRISPR Design Express for Academia. Every molecular biology lab on earth designs guide RNAs. The enterprise platforms charge five figures annually. The free web tools are, charitably, not great. There’s a gap between “free and unreliable” and “enterprise and expensive” that nobody has filled well. A per-design service — researcher submits a gene and region, receives ranked guides with off-target profiles and donor templates — fills that gap. Academic core facilities charge $100 to $500 per design with weeks-long backlogs. We produce the result in minutes.

Pharmacogenomics Reports for Clinical Pharmacies. This is the lowest-friction genomics service to sell. No IRB complexity. No research classification headaches. A pharmacist uploads a patient’s variant file, the system returns drug-gene interactions and dosing adjustments formatted as a one-page clinical report. The market is real — major pharmacy chains are actively piloting pharmacogenomic programs. The infrastructure is already built. The output is already clean.

Amplicon Edit Quantification for Gene Therapy CROs. Contract research organizations running CRISPR experiments need to quantify editing efficiency from amplicon sequencing data. It’s tedious, repetitive, and algorithmically solved. Upload a FASTQ, get back editing frequency with statistical confidence. Per-sample pricing, high volume, recurring revenue.

Variant Interpretation-as-a-Service. Take any annotated variant file. Return a tiered pathogenicity classification with evidence citations. Genetic counselors spend hours doing this manually per variant. The algorithm does it in seconds.

Bleeding Disorder Screening Panel. A complete genomic assessment for inherited bleeding disorders — von Willebrand factor variants, coagulation factor mutations, fibrinolytic pathway markers. Paired with the clinical decision-support tools already deployed: factor dosing, desmopressin prediction, trial matching. Per-patient pricing for hematology treatment centers.

The cure pipeline

This is the slide that makes investors lean forward.

A patient walks in with a genome. The system screens across 14 disease panels and 700+ genes. It interprets the variants — pathogenicity, inheritance patterns, drug-gene interactions. It matches the patient’s specific genotype to every currently recruiting clinical trial in the federal database. It connects them: one report, one session, same day.

The example is real. A patient with a suspected inherited bleeding disorder. The system identifies a von Willebrand factor variant, classifies it as Type 2B, flags that desmopressin is contraindicated (this is the kind of mistake that can cause harm if a clinician doesn’t know the subtype), calculates the appropriate factor replacement dose, and pulls three currently recruiting gene therapy trials for von Willebrand Disease — all in a single analysis session.

Traditional path: referral to a genetic counselor (six weeks), lab processing (four to twelve weeks), trial search (manual, if anyone thinks to do it at all). Our path: hours. Not because we’re smarter than the traditional system. Because we removed the bottlenecks.

The honest math

Let me put rough numbers on this, because investors and skeptics alike deserve arithmetic, not vibes.

Phase zero (now through next two months): Validate with pilot customers. Wrap existing REST services. Build three paying relationships. Revenue target: $0. Investment: $0. This is the “prove someone will pay for this” phase.

Phase one (months three to six): Ten paying customers. Pharmacogenomic reports and CRISPR design services live. Revenue target: $2,000 to $5,000 per month. Investment: $500 to $2,000 monthly for hosting, domains, and compliance groundwork.

Phase two (months six to twelve): Thirty-plus customers. Bleeding disorder decision support deployed to hematology treatment centers. Revenue target: $10,000 to $25,000 per month. The math: approximately 140 hemophilia treatment centers in the United States. A subscription model at $500 to $2,000 per clinic per month for genomic decision support is a $70,000 to $280,000 annual addressable market from that single vertical.

Phase three (year two): Multi-site deployment. White-label partnerships with hospital systems. Revenue target: $50,000 to $100,000 per month. This requires clinical validation studies and sales infrastructure. It also requires the kind of trust that only comes from Phase One and Two customers vouching for the service.

What we’re not

Let me be clear about the edges, because credibility requires honesty about limitations.

We don’t have clinical accreditation. The.lab is a research platform, not a clinical laboratory. Every output is decision support, not diagnosis. This is a feature, not a bug — it means we can operate without the multi-year, multi-million-dollar certification process that constrains hospital-based labs. But it means clinicians need to be in the loop. The system advises. The doctor decides.

We don’t have population-scale data. One genome — even a deeply analyzed one — doesn’t give you the statistical power of 150,000 genomes. Our variant classifications are algorithmic, not committee-curated. For well-characterized variants, this is fine. For variants of uncertain significance, expert review is still essential.

We don’t have diverse reference data. Our primary reference databases skew European-descent. For non-European ancestry, the accuracy of risk scores and variant frequency estimates drops. This is a known limitation of the field, not unique to us, and the global genomics community is actively working to close this gap.

What we are

A computational genomics facility that, on a per-patient basis, already matches the analysis depth of leading academic medical centers. Running on open-source software. Operating at zero marginal cost. Delivering same-day results. Integrated with clinical trial databases in real time. And equipped with a CRISPR design suite that no hospital system currently offers alongside its diagnostic pipeline.

The computational layer of clinical genomics has become commodity. The tools are free. The databases are open. The infrastructure is affordable. The only remaining barrier is knowing how to assemble the pipeline, interpret the results, and build the clinical workflows around it.

We’ve assembled it. We’re interpreting it. The workflows are next.

The investor playbook

Here’s what turns this from a blog into a company. Six moves. Six weeks. Total cost: zero.

#1 Published case study. One real patient. Full pipeline. Anonymized report as a downloadable PDF on this site. Not a screenshot. Not a summary. The actual clinical narrative: patient has X condition, traditional path takes Y weeks and costs Z dollars, the.lab did it in hours for the cost of electricity. This is the “one slide” that every investor meeting starts with. You have the data. You have the patient. The Jacob bleeding disorder report is already built.

#2 Live interactive demo. Not a video. Not a PDF. An actual web form where an investor, a scientist, or a curious stranger types “TP53” and gets back ranked guide RNAs with off-target profiles in under 60 seconds. The REST APIs already exist. You need one HTML page with a form and a results panel. Every investor deck has a “demo” slide; ours would have a URL they can try during the meeting. Nothing deflates skepticism like “go ahead, try it right now.”

#3 Published benchmark. Run the variant interpretation engine against the ClinVar reference set — the gold standard for clinical variant classification. Measure concordance. Publish the numbers. If the algorithm agrees with ClinVar’s expert-curated classifications 92%+ of the time, that’s a number investors can Google. If it’s lower, we know what to fix before we pitch. Either way, we’ve done something that most genomics startups skip because it’s tedious and the results might be humbling. We’re not most startups.

#4 Pricing page. Put it on the site: “API Access.” Show the tiers. Show the per-call or per-report pricing. Show the enterprise contact form. You don’t have to honor these prices yet. But a public pricing page does two things: it makes the business look real, and it forces you to actually think about unit economics. “CRISPR Design: $75/design. Variant Interpretation: $150/genome. PGx Report: $50/report. Enterprise: contact us.” That page, sitting next to the live demo and the case study, turns a blog into a product.

#5 Three letters of intent. You don’t need paying customers yet. You need three credible institutions — or clinicians, or lab directors — who will sign a one-paragraph document saying “we intend to evaluate this platform for [specific use case].” A hematology treatment center for the bleeding disorder tools. An academic PI for the CRISPR design service. A clinical pharmacist for PGx reports. One LOI is anecdotal. Three is a market signal.

#6 Cure pipeline dashboard. Build a page that shows: “We screen for 14 disease panels. Here are the 14. For each one, here’s the most advanced gene therapy or clinical trial currently recruiting. Here’s how the.lab connects a patient’s genotype to that trial in real time.” This reframes the entire business from “we run bioinformatics tools” to “we are the connective tissue between a patient’s genome and the therapy that might save their life.” That’s the story investors want to hear.

What’s next

Three things, in order of priority.

First: wrap the existing services as clean, documented APIs with billing integration. The hardest engineering is done. The remaining work is packaging.

Second: identify three pilot customers — a hematology treatment center, an academic research lab, and a clinical pharmacy — and run them through the full service for free. Collect feedback. Iterate on the output format. Build the case studies.

Third: validate the clinical decision-support tools against published outcomes. The desmopressin predictor, the factor dosing calculator, and the bleeding assessment scorer all produce outputs that can be compared against published clinical data. This validation is what turns “interesting technology” into “trustworthy tool.”

The most advanced single-patient genomics platform in North America is running on a cluster of servers, powered by open-source software, operated by an AI, and funded by the same person whose genome started the whole thing.

The question was never whether this technology works. It works. The question is whether it can sustain itself.

We’re about to find out.

Note on tools and licensing: the.lab runs on standard, open-source genomics software — the same tools used by research institutions worldwide. These tools are available under their respective open-source licenses for private use by all parties. Open-source does not mean unlicensed; each tool carries specific terms that we respect and follow. Rather than enumerate individual products in a public forum, we describe capabilities by function.